Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
56 resources available:
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
Source:
www.businesswire.com
Aug 30, 2024
myBinder
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Source:
investors.alnylam.com
Jun 24, 2024
myBinder
AstraZeneca advances scientific leadership in haematology at ASH 2023
Source:
www.astrazeneca.com
Nov 29, 2023
myBinder
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Source:
www.biospace.com
Oct 9, 2023
myBinder
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting
Source:
www.businesswire.com
Sep 13, 2023
myBinder
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
Source:
www.hcplive.com
Aug 27, 2023
myBinderShow more
6 resources available:
India’s first Amyloid Center inaugurated at Amrita Hospital
Source:
health.economictimes.indiatimes.com
May 12, 2023
myBinder
oneAMYLOIDOSISvoice.com Support Group Platform Begins Empowering the Amyloidosis Community With Invaluable Info About Amyloidosis
Source:
www.prweb.com
May 14, 2019
myBinder
HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients With Treatment Costs
Source:
www.prnewswire.com
Apr 23, 2019
myBinder
Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain Amyloidosis
Source:
seekingalpha.com
Feb 1, 2019
myBinder
SCMR Partners With Foundation to Promote March as Amyloidosis Awareness Month
Source:
markets.businessinsider.com
Mar 13, 2019
myBinder12 resources available:
Hereditary amyloidosis in Brazil: a focus on access to diagnosis and treatment
Source:
rarerevolutionmagazine.com
Mar 27, 2023
myBinder
Amyloidosis, A Tricky Diagnosis, Can Be Traced to Vietnam and Exposure to Agent Orange
Source:
www.uchealth.org
Mar 14, 2022
myBinder
With CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare Diseases
Source:
www.washingtonpost.com
Feb 5, 2022
myBinder
He Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped It
Source:
www.npr.org
Jun 26, 2021
myBinder
Show more
78 resources available:
Virtual hATTR Amyloidosis Educational Program – June 18, 2024 10:00 AM CT
Source:
bit.ly
Jun 12, 2024
myBinder
San Diego — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 27, 2024
Source:
lp.constantcontactpages.com
Apr 27, 2024
myBinder
Portland — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 20, 2024
Source:
lp.constantcontactpages.com
Apr 20, 2024
myBinder
Philadelphia — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 20, 2024
Source:
lp.constantcontactpages.com
Apr 20, 2024
myBinder
Kansas City — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 20, 2024
Source:
lp.constantcontactpages.com
Apr 20, 2024
myBinder
Amyloidosis Support Groups Webinar on Cardiac Amyloidosis
Source:
amyloidosissupport.zoom.us
Jan 20, 2024
myBinderShow more
22 resources available:
Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals
Source:
bmjopen.bmj.com
Mar 1, 2024
myBinder
A vision toward a more holistic approach to care in hereditary ATTR amyloidosis
Source:
editions.rarerevolutionmagazine.com
Nov 9, 2023
myBinder
Amyloidosis now a hot topic in cardiac imaging due to new drug treatment
Source:
cardiovascularbusiness.com
Jul 11, 2023
myBinder
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
Source:
www.ultromics.com
Apr 26, 2023
myBinder
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Source:
www.prnewswire.com
Mar 7, 2023
myBinder
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
Source:
rarediseases.org
Jan 4, 2023
myBinderShow more
7 resources available:
CMAF Benefit Dinner: Evening of Corvettes, Dinner & Fun!
Source:
chipmiller.org
Aug 26, 2022
myBinder
Show more
